BTG
Genetically Engineered Drugs
Company Overview
Snapshot
Founded in September 1980, BTG operates with 201–500 employees. The company has secured $26.93M across 4 funding rounds from 1 investor. A significant milestone occurred in May 2018 when Ferring Pharmaceuticals invested in the company.
Business overview
BTG (Bio-Technology General Israel) is an integrated biopharmaceutical services company specializing in the development and manufacturing of healthcare products derived from genetic engineering and biotechnology processes. The company's core products include Biolon, an injectable system for ophthalmic surgeries; Euflexxa, a treatment for osteoarthritis knee pain; and recombinant human growth hormone for treating Turner syndrome and growth hormone deficiency. BTG serves the biopharmaceutical and healthcare markets, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In September 2023, BTG articulated its vision for Israel to become a global leader in biological GMP production. This strategic outlook signals the company's commitment to advancing biopharmaceutical manufacturing capabilities within the region, potentially attracting further investment and partnerships in the biotech sector.
Log in to access full profile ›Company Intelligence Q&A
- When was BTG acquired?
- BTG was acquired by Ferring Pharmaceuticals in January 2005.
- What is BTG's vision for Israel's biotech industry?
- In September 2023, BTG expressed a vision for the State of Israel to become a world leader in biological GMP production.
- What was the investment by Ferring Pharmaceuticals in BTG's Israeli unit?
- In May 2018, Ferring Pharmaceuticals invested in BTG's Israeli unit, as reported by Globes.
- What is Euflexxa?
- Euflexxa is a BTG product designed to help relieve knee pain due to osteoarthritis, delivered as an intra-articular injection containing 1% fermentation-derived sodium hyaluronate.
- What is the primary use of BTG's recombinant human growth hormone?
- Developed in the 1980s and approved in 1988, BTG's recombinant human growth hormone is used to treat Turner syndrome and growth hormone deficiency in children.